Concomitant EGFR mutations/ALK rearrangements: beyond a simple dual target

Despite conventionally considered as mutually exclusive, concurrent EGFR activating mutations and ALK rearrangements in non-small cell lung cancer (NSCLC) are increasingly described, due to more sensitive detection methods (1-3). The rate of double mutations is about 1.3% of NSCLC (2).